Scott C. Bell

Overview

Best Publications

• A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

  Bonnie W. Ramsey;Jane Davies;N. Gerard McElvaney;Elizabeth Tullis

  2384
  Citations

• Genetic mechanisms of critical illness in Covid-19.

  E. Pairo-Castineira;E. Pairo-Castineira;S. Clohisey;L. Klaric;A. D. Bretherick

  1445
  Citations

• Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals

  David J. Lederer;Scott C. Bell;Richard D. Branson;James D. Chalmers

  738
  Citations

• European Cystic Fibrosis Society Standards of Care: Best Practice guidelines

  Alan R. Smyth;Scott C. Bell;Snezana Bojcin;Mandy Bryon

  710
  Citations

• ECFS best practice guidelines: the 2018 revision

  Carlo Castellani;Alistair J.A. Duff;Alistair J.A. Duff;Scott C. Bell;Harry G.M. Heijerman

  702
  Citations

• Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial

  J Wolter;S Seeney;S Bell;S Bowler

  642
  Citations

• Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.

  Josephine M Bryant;Josephine M Bryant;Dorothy M Grogono;Dorothy M Grogono;Daniela Rodriguez-Rincon;Isobel Everall

  590
  Citations

• The future of cystic fibrosis care: a global perspective

  Scott C Bell;Marcus A Mall;Hector Gutierrez;Milan Macek

  529
  Citations

• The Rise of Non-Tuberculosis Mycobacterial Lung Disease

  Champa N. Ratnatunga;Viviana P. Lutzky;Andreas Kupz;Andreas Kupz;Denise L. Doolan;Denise L. Doolan

  450
  Citations

• A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

  Michael P Boyle;Scott C Bell;Michael W Konstan;Susanna A McColley

  394
  Citations

• Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease

  Rajiv Khanna;Scott Bell;Martina Sherritt;Andrew Galbraith

  378
  Citations

• Genetic modifiers of liver disease in cystic fibrosis.

  Jaclyn R. Bartlett;Kenneth J. Friedman;Simon C. Ling;Rhonda G. Pace

  316
  Citations

• Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.

  Shawn D Aaron;Katherine L Vandemheen;Wendy Ferris;Dean Fergusson

  289
  Citations

• Antibiotic Susceptibilities of Pseudomonas aeruginosa Isolates Derived from Patients with Cystic Fibrosis under Aerobic, Anaerobic, and Biofilm Conditions

  Dominic Hill;Barbara Rose;Aniko Pajkos;Michael Robinson

  270
  Citations

• Neutrophils in cystic fibrosis

  D G Downey;S C Bell;J S Elborn

  264
  Citations

• Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals.

  Daniel E. Leisman;Michael O. Harhay;David J. Lederer;David J. Lederer;Michael Abramson

  261
  Citations

• New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls

  Scott C. Bell;Kris De Boeck;Margarida D. Amaral

  218
  Citations

• Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Thoracic Society of Australia and New Zealand guidelines

  Anne B Chang;Scott C Bell;Paul J Torzillo;Paul T King;Paul T King

  213
  Citations

• Microvascular complications in cystic fibrosis-related diabetes mellitus: a case report.

  Andrew I.R. Scott;Belinda E. Clarke;Helen Healy;Michael D'Emden

  16
  Citations

• Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium

  J. M. Bryant;D. M. Grogono;D. Rodriguez-Rincon;I. Everall

  0
  Citations